Tools

Search

Explore

Videos Channels Figures

Atmrix

About

Tools

Search

Explore

Videos Channels Figures

Atmrix

About

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Recent approvals of gene therapies and cell-based therapies have opened new avenues for biotech companies to create marketable products.

Video

YC

A Conversation with Elizabeth Iorns - Advice for Biotech Founders

@ Y Combinator

A Conversation with Elizabeth Iorns - Advice for Biotech Founders

10/03/18

Related Takeaways

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

The biotech industry is experiencing a surge in startups due to unprecedented access to capital and advancements in therapeutic modalities.

IF

Isa Fulford

05/08/25

@ Sequoia Capital

Deep research can provide insights across a broad range of topics, including specific gene therapies that have gained regulatory approval in the US.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

The future of biotech will likely involve products that patients are willing to pay for, focusing on conditions that significantly impact their quality of life.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Access to capital and FDA's development strategies for rare diseases have enabled small biotech companies to bring products to market without being acquired.

EI

Elizabeth Iorns

10/03/18

@ Y Combinator

Biotech MVPs are challenging to define because commercial revenue typically only comes after product approval, which many biotechs never achieve.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

EI

Elizabeth Iorns

09/14/17

@ Y Combinator

There is a growing interest from early-stage technology investors in funding biotech companies, with many successfully raising significant seed funding.

PB

Paul Buchheit

03/07/18

@ Y Combinator

When evaluating biotech companies, the demand for their product is often clear, but the challenge lies in their ability to deliver on that promise.